Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015
December 06, 2015 at 08:42 AM EST
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) ...
